AR105547A1 - Antibiótico de aminoglucósido para bacterias resistentes a múltiples fármacos - Google Patents
Antibiótico de aminoglucósido para bacterias resistentes a múltiples fármacosInfo
- Publication number
- AR105547A1 AR105547A1 ARP160102333A ARP160102333A AR105547A1 AR 105547 A1 AR105547 A1 AR 105547A1 AR P160102333 A ARP160102333 A AR P160102333A AR P160102333 A ARP160102333 A AR P160102333A AR 105547 A1 AR105547 A1 AR 105547A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- hydrogen atom
- amino
- hydroxyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
- C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
- C07H15/224—Cyclohexane rings substituted by at least two nitrogen atoms with only one saccharide radical directly attached to the cyclohexyl radical, e.g. destomycin, fortimicin, neamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
- C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
- C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
- C07H15/234—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se revela un compuesto o una de sus sales o solvatos farmacéuticamente aceptables, y una de sus composiciones farmacéuticas y su uso para prevenir o tratar enfermedades infecciosas y un método para prevenir o tratar enfermedades infecciosas usando aquellos regímenes. Este compuesto tiene una actividad antibacteriana contra bacterias tanto gram-positivas como gram-negativas y es de utilidad en la prevención o el tratamiento de enfermedades infecciosas causadas por estas bacterias. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula general (1) o una de sus sales o solvatos farmacéuticamente aceptables, en donde R¹ es un átomo de hidrógeno o un grupo hidroxilo; R² es un átomo de hidrógeno o un grupo amino; R³ es un átomo de hidrógeno, un átomo de halógeno, un grupo hidroxilo o un grupo amino; R⁴ es un átomo de hidrógeno, un átomo de halógeno, un grupo hidroxilo o un grupo amino, en donde R¹ y R⁴ pueden formar un enlace doble juntos; R⁵ es un átomo de hidrógeno, un grupo hidroxilo o un grupo amino; R⁶ es un átomo de hidrógeno, un grupo hidroxilo o un grupo amino; R⁷ es un átomo de hidrógeno, un grupo hidroxilo o un grupo amino; R⁸ es un átomo de hidrógeno, un grupo hidroxilo o un grupo amino; R⁹ y R¹⁰ son cada uno, de modo independiente, un átomo de hidrógeno, un grupo alquilo C₁₋₆, un grupo amino-alquilo C₁₋₆, un grupo guanidino-alquilo C₁₋₆, un grupo amino-cicloalquilo C₃₋₇, un grupo amino-cicloalquil C₃₋₇-alquilo C₁₋₆, un grupo amidino, un grupo azetidino opcionalmente sustituido con un grupo alquilo C₁₋₆, un grupo glicilo, un grupo sarcosilo, un grupo L-alanilo, un grupo D-alanilo, un grupo L-serilo, un grupo D-serilo, un grupo b-alanilo, un grupo L-isoserilo o un grupo D-isoserilo; y R¹¹ es un átomo de hidrógeno, un grupo hidroxilo o un átomo de flúor; excepto cuando (i) R¹, R⁴, R⁵, R⁸ y R¹¹ son grupos hidroxilo, R², R³, R⁶, R⁷, R⁹ y R¹⁰ son átomos de hidrógeno, (ii) R⁵, R⁸ y R¹¹ son grupos hidroxilo, R¹, R², R³, R⁴, R⁶, R⁷, R⁹ y R¹⁰ son átomos de hidrógeno, (iii) R¹, R⁵, R⁸ y R¹¹ son grupos hidroxilo, R², R³, R⁴, R⁶, R⁷, R⁹ y R¹⁰ son átomos de hidrógeno, (iv) R¹, R⁴, R⁵ y R⁸ son grupos hidroxilo, R², R³, R⁶, R⁷, R⁹, R¹⁰ y R¹¹ son átomos de hidrógeno, (v) R¹, R⁴, R⁵, R⁸ y R¹¹ son grupos hidroxilo, R², R³, R⁶ y R⁷ son átomos de hidrógeno, cualquiera de R⁹ o R¹⁰ es un átomo de hidrógeno, el otro es un grupo etilo o un grupo 2-aminoetilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015151250 | 2015-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105547A1 true AR105547A1 (es) | 2017-10-11 |
Family
ID=57884581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102333A AR105547A1 (es) | 2015-07-30 | 2016-07-29 | Antibiótico de aminoglucósido para bacterias resistentes a múltiples fármacos |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10617704B2 (es) |
| EP (2) | EP3330275A4 (es) |
| JP (1) | JP6938376B2 (es) |
| KR (1) | KR102590696B1 (es) |
| CN (1) | CN108026133B (es) |
| AR (1) | AR105547A1 (es) |
| AU (1) | AU2016300993B2 (es) |
| CA (1) | CA2993425A1 (es) |
| CL (1) | CL2018000228A1 (es) |
| CO (1) | CO2018001237A2 (es) |
| HK (1) | HK1254239A1 (es) |
| IL (1) | IL257151B (es) |
| MX (1) | MX2018001022A (es) |
| MY (1) | MY186959A (es) |
| NZ (1) | NZ740037A (es) |
| PH (1) | PH12018500202B1 (es) |
| RU (1) | RU2751634C2 (es) |
| SA (1) | SA518390825B1 (es) |
| SG (2) | SG10201913231RA (es) |
| TW (1) | TWI699372B (es) |
| UA (1) | UA123629C2 (es) |
| WO (1) | WO2017018528A1 (es) |
| ZA (1) | ZA201801312B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ740037A (en) * | 2015-07-30 | 2024-08-30 | Microbial Chemistry Res Foundation | New effective aminoglycoside antibiotic for multidrug-resistant bacteria |
| JP2020055749A (ja) * | 2017-01-27 | 2020-04-09 | 公益財団法人微生物化学研究会 | 多剤耐性菌に有効な新規アミノグリコシド抗生物質 |
| WO2018204358A1 (en) * | 2017-05-01 | 2018-11-08 | Wayne State University | Apramycin derivatives |
| JP2021138615A (ja) * | 2018-05-31 | 2021-09-16 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 多剤耐性菌に有効なアミノグリコシド抗生物質の製造方法 |
| CN116462721B (zh) * | 2023-04-18 | 2024-02-02 | 江南大学 | 抗菌性氨基糖苷衍生物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4424345A (en) | 1980-09-22 | 1984-01-03 | Eli Lilly And Company | 1-N-Acylated and 1-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides and process |
| JPS5782399A (en) * | 1980-09-22 | 1982-05-22 | Lilly Co Eli | 2-deoxystreptamine aminoglycoside derivative and manufacture |
| US4424344A (en) | 1980-09-22 | 1984-01-03 | Eli Lilly And Company | 2-N-Acylated and 2-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides and process |
| US4468513A (en) | 1980-09-22 | 1984-08-28 | Eli Lilly And Company | 2'-N-Acylated and 2'-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides |
| JPS5782398A (en) * | 1980-09-22 | 1982-05-22 | Lilly Co Eli | 2-deoxystreptamine aminoglycoside derivative |
| JPS5772999A (en) * | 1980-10-24 | 1982-05-07 | Shionogi & Co Ltd | Novel 5-deoxyapramycin |
| JPS5772998A (en) * | 1980-10-24 | 1982-05-07 | Shionogi & Co Ltd | Novel appamycin derivative |
| US4385585A (en) * | 1981-10-27 | 1983-05-31 | Copco, Inc. | Teakettle having whistle cap |
| US4379917A (en) | 1981-12-24 | 1983-04-12 | Eli Lilly And Company | 6"-(Substituted)-apramycin antibiotic derivatives and intermediates and starting materials therefor |
| US4360665A (en) | 1981-12-24 | 1982-11-23 | Eli Lilly And Company | 4"-N-(Substituted)-apramycin antibiotic derivatives and intermediates therefor |
| US4458065A (en) * | 1983-02-17 | 1984-07-03 | Eli Lilly And Company | 7-N-(Substituted-apramycin antibiotic derivatives and intermediates therefor |
| AU2007235408A1 (en) | 2006-04-07 | 2007-10-18 | E.I. Du Pont De Nemours And Company | Processes for chemical synthesis of lipochitooligosaccharides |
| CN102942603B (zh) * | 2006-06-02 | 2016-01-20 | 明治制果药业株式会社 | 新的氨基糖苷类抗生素 |
| ES2613936T3 (es) | 2007-11-21 | 2017-05-29 | Achaogen, Inc. | Análogos de aminoglucósido antibacterianos |
| TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
| EP2616079B1 (en) | 2010-09-13 | 2015-10-14 | University of Zürich | Treatment of bacterial infectious diseases |
| WO2013191550A1 (en) * | 2012-06-20 | 2013-12-27 | Rijksuniversiteit Groningen | Regioselective diazotation of aminoglycosides |
| RU2491921C1 (ru) * | 2012-07-11 | 2013-09-10 | Общество с ограниченной ответственностью "Опытно-технологическая фирма "Этрис" | Способ лечения мастита у коров в сухостойный период |
| NZ740037A (en) * | 2015-07-30 | 2024-08-30 | Microbial Chemistry Res Foundation | New effective aminoglycoside antibiotic for multidrug-resistant bacteria |
-
2016
- 2016-07-29 NZ NZ740037A patent/NZ740037A/en unknown
- 2016-07-29 UA UAA201802040A patent/UA123629C2/uk unknown
- 2016-07-29 WO PCT/JP2016/072400 patent/WO2017018528A1/ja active Application Filing
- 2016-07-29 MX MX2018001022A patent/MX2018001022A/es unknown
- 2016-07-29 CA CA2993425A patent/CA2993425A1/en active Pending
- 2016-07-29 EP EP16830631.4A patent/EP3330275A4/en not_active Withdrawn
- 2016-07-29 EP EP19154615.9A patent/EP3498723A1/en active Pending
- 2016-07-29 RU RU2018107150A patent/RU2751634C2/ru active
- 2016-07-29 JP JP2017530947A patent/JP6938376B2/ja active Active
- 2016-07-29 CN CN201680044421.1A patent/CN108026133B/zh active Active
- 2016-07-29 TW TW105124162A patent/TWI699372B/zh active
- 2016-07-29 SG SG10201913231RA patent/SG10201913231RA/en unknown
- 2016-07-29 US US15/747,581 patent/US10617704B2/en active Active
- 2016-07-29 KR KR1020187005745A patent/KR102590696B1/ko active IP Right Grant
- 2016-07-29 SG SG11201800510WA patent/SG11201800510WA/en unknown
- 2016-07-29 MY MYPI2018700342A patent/MY186959A/en unknown
- 2016-07-29 AU AU2016300993A patent/AU2016300993B2/en active Active
- 2016-07-29 AR ARP160102333A patent/AR105547A1/es unknown
-
2018
- 2018-01-25 PH PH12018500202A patent/PH12018500202B1/en unknown
- 2018-01-25 IL IL257151A patent/IL257151B/en active IP Right Grant
- 2018-01-26 CL CL2018000228A patent/CL2018000228A1/es unknown
- 2018-01-28 SA SA518390825A patent/SA518390825B1/ar unknown
- 2018-02-06 CO CONC2018/0001237A patent/CO2018001237A2/es unknown
- 2018-02-26 ZA ZA2018/01312A patent/ZA201801312B/en unknown
- 2018-10-18 HK HK18113382.9A patent/HK1254239A1/zh unknown
-
2020
- 2020-01-22 US US16/749,191 patent/US11135234B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105547A1 (es) | Antibiótico de aminoglucósido para bacterias resistentes a múltiples fármacos | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| CY1124680T1 (el) | Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| PH12017502418A1 (en) | 3-tetrazolyl-benzene-1,2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112018007772A2 (pt) | compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer | |
| BR112016029846A2 (pt) | ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo? | |
| BR112016030733A2 (pt) | Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis | |
| NZ729252A (en) | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof | |
| BR112016011016A8 (pt) | derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica. | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| EA201691600A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| BR112019000453A2 (pt) | combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas | |
| CY1120602T1 (el) | [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| BR112018070514A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição |